Screening of circulating tgf-β levels and its clinicopathological significance in human breast cancer

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 737-742

  Panis, Carolina ^a   Herrera, Ana Cristina ^a   Victorino, Vanessa Jacob ^a   Aranome, Adriano Martin Felis ^a   Cecchini, Rubens ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Breast cancer; Prognostic factors; TGF 1

Indexed keywords

DOXORUBICIN; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 84875900723     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Nguyen DH, Martinez-Ruiz H and Barcellos-Hoff MH: Consequences of epithelial of stromal TGF-β1 depletion in the mammary gland. J Mammary Gland Biol Neoplasia 16: 147-155, 2011.
2. Knnabe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Deryinc R and Dickson RB: Evidence that transforming growthbeta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48(3): 417-428, 1987.
3. Barcellos-Hoff MH, Chaterjee A and Dix TA: Redox-mediated activation of latent transforming growth factor beta 1. Mol Endocrinol 10(9): 1077-1083, 1996.
4. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y and Moses HL: Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 119(6): 1571-1582, 2009.
5. Classen S, Muth C, Debey-Pascher S, Eggle D, Beyer M, Mallmann MR, Rudlowski C, Zander T, Polcher M, Kuhn W, Lahn M, Schultze JL and Staratschek-Jox A: Application of Tcell-based trasncriptomics to identify three candidate biomarkers for monitoring anti-TGF-betaR therapy. Pharmacogenet Genomics 20(3): 147-156, 2010.
6. Arjaans M, Oude Munnink TH, Timer-Bosscha H, Reiss M, Walenkamp AM, Lub-de-Hooge MN and de Vries EG, Schroder CP: Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for antitumor therapy and tumor imaging. Pharmacol Ther 135(20): 123-132, 2012.
7. Ohsawa Y, Okada T, Nishimastu SI, Ishizaki M, Suga T, Fujino M, Murakami T, Uchino M, Tsuchida K, Noji S, Hinohara A, Shimizu T and Sunada Y: An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin-3-deficient muscular ditrophy. Lab Invest 92(8): 1100-1114, 2012.
8. Seth P, Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen YJ, Zhang Z, Du H, Brendler CB, Xiao X, Pienta KJ, Guise T, Lee C, Stern PH and Stock S: Systemic delivery of oncolytic adenovirus targeting transforming growth factor beta inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther 23(8): 871-882, 2012.
9. Biswas S, Nyman JS, Alvarez J, Chakrabarti A, Ayres A, Sterling J, Edwards J, rana T, Johnson R, Perrien DS, Lonning S, Shyr Y, Matrisian LM and Mundy GR: Anti-transforming growth factor β antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PloS One 6(11): e27090, 2011.
10. Garrison K, Hahn T, Lee WC, Ling LE, Weinberg AD and Akporyaye ET: The small molecule TGF-β signalling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother 61(4): 511-521, 2012.
11. Lin S, Yang J, Elkahloun AG, Bandyopadhyay A, Wang L, Cornell JE, Yeh IT, Agyin J, Tomlinson G and Sun LZ: Attenuation of TGF-β signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic RAS-mediated metastatic transformation in human mammary epithelial cells. Mol Biol Cell 23(8): 1569-1581, 2012.
12. Naber HP, Wiercinska E, Pardali E, van Laar T, Nirmala E, Sundqvist A, van Dam H, van der Horst G, van der Pluijm G, Heckmann B, Danem EH and Ten Dijke P: BMP-7 inhibits TGF-β-induced invasion of breast cancer cells through inhibition of integrin β(3) expression. Cell Oncol 35(1): 19-28, 2012.
13. Perusinghe NP, Monaghan P, ÓHare MJ, Ashley S and Guterson BA: Effects of growth factors on proliferation on basal and luminal cells in human breast epithelial explants in serum-free cultures. In Vitro Cell Dev Biol 28(20): 90-96, 1992.
14. Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim SE, Yap HL, Yeo WL, Tan P, Tan SH, McLeod H and Goh BC: Chemotherapy-induced tumor gene expression changes in human breast cancers. Pharmacogenet Genomics 19(3): 181-192, 2009.
15. Theohari I, Giannopoulou I, Magkou C, Nomikos A, Melissaris S and Nakopoulou L: Differential effect of the expression of TGF-β pathway inhibitors, Smad-7 and Ski, on invasive breast carcinomas: Relation to biologic behavior. APMIS 120(2): 92-100, 2012.
16. Drabsch Y and Dijke P: TGF-β signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia 16: 97-108, 2011.
17. Rhee J, Han SW, Cha Y, Ham HS, Kim HP, Oh DY, Im SA, Park JW, Ro J, Lee KS, Park IH, Im YH, Bang YJ and Kim TY: High serum TGF-β predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. Breast Cancer Res Treat 125(1): 107-114, 2011.
18. Herrera ACSA, Panis C, Victorino VJ, Campos FC, Colado-Simão AN, Cecchini AL and Cecchini R: Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients. Cancer Immunol Immunother 61(11): 2193-2201, 2012.
19. Panis C, Victorino VJ, Herrera ACSA, Freitas LF, deRossi T, Campos FC, Colado Simão NA, Barbosa DS, Pinge-Filho P, Cecchini R and Cecchini AL: Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat 133(3): 881-888, 2012.
20. Dave H, Shah M, Trivedi S and Shukla S: Prognostic utility of circulating transforming growth factor beta 1 in breast cancer patients. Int J Biol Markers 27(1): 53-59, 2012.
21. Chod J, Zavadova E, Halaska MJ, Strnad P, Fucikova T and Rob L: Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol 29(6): 613-616, 2008.
22. González-Zuloeta Ladd AM, Arias-Vásquez A, Siemens C, Coebergh JW, Hofman A, Witteman J, Uitterlinden A, Stricker BH and van Duijin CM: Transforming growth factor beta 1 Leu10Pro polymorphism and breast cancer morbidity. Eur J Cancer 43(2): 371-374, 2007.
23. Baxley SE and Serra R: Inhibiting breast cancer progression by exploiting TGFbeta signaling. Curr Drug target 11(90): 1089-1102, 2010.
24. Taylor MA, Lee Yh and Schiemann WP: Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr 15(3): 117-132, 2011.
25. Band AM and Laiho M: Crosstalk of TGF-β and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 16: 109-115, 2011.
26. Taylor MA, Parvani JG and Schiemann WP: The pathophysiology of epithelial mesenchymal transition indiced by transforming growth factor-β in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 15: 169-190, 2010.
27. Figueroa JD, Flandres KC, Garcia-Closas M, Anderson WF, Yang XR, Matsuno RK, Duggan MA, Pfeiffer RM, Ooshima A, Cornelison R, Gierach GL, Brinton LA, Lissowska J, Peplonska B, Wakefield LM and Sherman ME: Expression of TGF-beta signaling factors in invasive breast cancer: Relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat 121(3): 727-735, 2010.
28. Al-Shabanah OA, Aleisa AM, Hafez MM, Al-Rejaie SS, Al-Yahya AA, Bakheet SA, Al-Harbi MM and Sayed-Ahmed MM: Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through Tgf-β/Smad p53 pathway in rat model. Oxid Med Cell Longev 619185, 2012.
29. Song YJ, li J, Xie XF, Wanf H and Li QX: Effects of amlodipine on Tgf-β-induced Smad2, 4 expressions in adriamycin toxicity of rat mesangial cells. Arch Toxicol 85(6): 663-668, 2011.
30. Taniguchi Y, Kawano K, Minowa T, Sugino T, Shimojo Y and Maitani Y: Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor. Cancer Sci 101(10): 2207-2213, 2010.
31. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Raffty BG and Reiss M: Alterations of SMAD signaling in human breast carcinoma are associated with poor outcome: A tissue microarray study. Cancer Res 62(2): 497-505, 2002.
32. Cuy Y, Robertson J, Maharaj S, Waldhauser L, Niu J, Wang J, Farkas L, Kolb M, Gauldie J. Oxidative stress contributes to the induction and persistence of TGFβ1-induced pulmonary fibrosis. Int J Biochem Cell Biol 43(8): 1122-1133, 2011.
33. Panis C, Lemos LGT, Victorino VJ, Herrera ACSA, Campos FC, Colado Simão NA, Pinge-Filho P, Cecchini AL and Cecchini R: Immunological effects of Taxol and adriamicyn in breast cancer patients. Cancer Immunol Immunother 61(4): 481-488, 2012.
34. Victorino VJ, Panis C, Campos FC, Cayres RC, Colado-Simão AN, Oliveira SR, Herrera ACSA, Cecchini AL and Cecchini R: Decreased antioxidant profile and increased antioxidant capacity in naturally postmenopausal women. Age doi 10.1007/s11357-012-9431-9, 2012.